Stock CCCC C4 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
6.43 USD -1.68% Intraday chart for C4 Therapeutics, Inc. +3.04% +13.81%
08/04 C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 CI
18/03 C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index CI

Business Summary

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Number of employees: 145

Sales per Business

USD in Million2022Weight2023Weight Delta
Targeted Protein Degradation
100.0 %
31 100.0 % 21 100.0 % -33.25%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
31 100.0 % 21 100.0 % -33.25%

Managers

Managers TitleAgeSince
Andrew Hirsch CEO
 Chief Executive Officer 53 14/20/14
Kendra Adams DFI
 Director of Finance/CFO 48 20/20/20
Mayra Reyes-Armour CTO
 Chief Tech/Sci/R&D Officer - 01/21/01
Stewart Fisher CTO
 Chief Tech/Sci/R&D Officer 57 01/16/01
Leonard Reyno CTO
 Chief Tech/Sci/R&D Officer 61 10/23/10
Courtney Solberg IRC
 Investor Relations Contact - -
Mark Mossler AUD
 Comptroller/Controller/Auditor 51 01/23/01
Scott Boyle PRN
 Corporate Officer/Principal 46 01/22/01
Adrian Bignami PRN
 Corporate Officer/Principal - 01/21/01
Jolie Siegel LAW
 General Counsel 47 01/20/01

Members of the board

Members of the board TitleAgeSince
Bruce Downey CHM
 Chairman 76 01/15/01
Glenn Dubin BRD
 Director/Board Member 67 12/21/12
Bihua Chen PRN
 Corporate Officer/Principal 55 01/15/01
Donna Grogan BRD
 Director/Board Member 67 29/22/29
Owen Hughes BRD
 Director/Board Member 49 20/11
Kenneth Anderson FOU
 Founder 72 01/15/01
Andrew Hirsch CEO
 Chief Executive Officer 53 14/20/14
Malcolm Salter BRD
 Director/Board Member 84 01/15/01
Utpal Koppikar BRD
 Director/Board Member 53 16/22/16
Laura Bessen BRD
 Director/Board Member 61 29/22/29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,600,669 60,834,824 ( 88.68 %) 0 88.68 %

Shareholders

NameEquities%Valuation
SSgA Funds Management, Inc.
10.43 %
7,153,280 10.43 % 58 M $
BETTA PHARMACEUTICALS CO., LTD.
8.116 %
5,567,928 8.116 % 45 M $
Wasatch Advisors, Inc.
8.042 %
5,516,718 8.042 % 45 M $
RA Capital Management LP
7.111 %
4,878,000 7.111 % 40 M $
Wasatch Advisors, Inc.
6.310 %
4,328,479 6.310 % 35 M $
Commodore Capital LP
5.539 %
3,800,000 5.539 % 31 M $
Lynx1 Capital Management LP
4.569 %
3,134,396 4.569 % 26 M $
T. Rowe Price International Ltd.
3.730 %
2,558,480 3.730 % 21 M $
Soleus Capital Management LP (Investment Management)
3.726 %
2,555,996 3.726 % 21 M $
Point72 Asset Management LP
3.370 %
2,312,059 3.370 % 19 M $

Company contact information

C4 Therapeutics, Inc.

490 Arsenal Way Suite 120

02472, Watertown

+

http://www.c4therapeutics.com
address C4 Therapeutics, Inc.(CCCC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for C4 Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.43 USD
Average target price
17.22 USD
Spread / Average Target
+167.84%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
C4 THERAPEUTICS, INC. Stock C4 Therapeutics, Inc.
+13.81% 450M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CCCC Stock
  4. Company C4 Therapeutics, Inc.